ArticleCureus2025
Prognostic Role of Pyruvate Kinase M2 in High-Grade Gliomas: A Quantitative Immunohistochemistry Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- C3G Downregulation Enhances Stemness in Glioblastoma Cells by Promoting PKM2 Upregulation.International journal of biological sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma (GBM) and grade 4 astrocytoma (ASTROG4) are aggressive primary brain tumors characterized by rapid growth, invasiveness, and poor prognosis, differentiated by the presence or absence of isocitrate dehydrogenase (IDH) mutation according to the World Health Organization (WHO) 2021 classification. Essential molecular markers, in addition to IDH mutations, include alpha-thalassemia/mental retardation syndrome X-linked (ATRX) loss and p53 expression, which significantly influence their classification and prognosis. Pyruvate kinase M2 (PKM2), a critical enzyme in tumor metabolism, has been implicated in glioma progression, but its prognostic significance remains unclear.
methodsThis prospective study aimed to quantitatively measure PKM2 immunohistochemistry (IHC) expression in GBM (IDH wildtype) versus ASTROG4 (IDH R132H mutant), to assess the correlation between PKM2 expression and prognosis in these two patient groups, and to investigate the prognostic significance of ATRX and p53 expression in relation to PKM2 levels. A total of 67 patients with high-grade gliomas (43 GBM, 24 ASTROG4) were analyzed using IHC for IDH1, ATRX, p53, and PKM2. PKM2 expression was quantified using 3DHISTECH (Budapest, Hungary) image analysis software, and correlations with clinical parameters, survival, and other molecular markers were evaluated. Kaplan-Meier survival analysis and Cox regression models assessed the impact of PKM2 expression and clinical factors on prognosis.
resultsPKM2 expression was observed in both GBM and ASTROG4, with no significant differences in positivity rates. However, high PKM2 intensity scores significantly correlated with increased mortality risk (p=0.041). ATRX-negative tumors showed elevated PKM2 levels, suggesting compensatory metabolic adaptations. ASTROG4 cases had better survival outcomes than GBM. Severe preoperative motor deficits were associated with a threefold increase in mortality risk, highlighting the critical role of clinical factors in determining prognosis.
conclusionsPKM2 plays an important role in glioma metabolism and can serve as a potential therapeutic target. Its association with ATRX highlights its involvement in tumor progression and genomic instability. Combining molecular markers with clinical parameters can improve prognostic accuracy and inform personalized treatment strategies for astrocytic tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.